spectively). The operation performed, the tumour stage and grade, the extent of residual disease, and the follow-up outcomes were evaluated. Results: Of 14,850 patients who had appendectomies, 215 (1.45%) had histologically confirmed ANEN. Four patients had synchronous non-ANEN malignancies. One hundred and ninety-three patients had index appendectomy. Seventeen patients (7.9%) had lymph node metastases within the mesoappendix. Forty-nine patients underwent RH after appendectomy. The percentages of 30-day morbidity and mortality after RH were 2 and 0%, respectively. Twelve patients (24.5%) receiving completion RH were found to have lymph node metastases. Two patients had liver metastases, both of them synchronous. The median follow-up was 38.5 months (range 1-143). No patient develKeywords Appendix · Neuroendocrine tumours · Neoplasms · Appendectomy · Hemicolectomy Abstract Background: Appendiceal neuroendocrine neoplasms (ANEN) are mostly indolent tumours treated effectively with simple appendectomy. However, controversy exists regarding the necessity of oncologic right hemicolectomy (RH) in patients with histologic features suggestive of more aggressive disease. We assess the effects of current guidelines in selecting the surgical strategy (appendectomy or RH) for the management of ANEN. Methods/Aims: This is a retrospective review of all ANEN cases treated over a 14-year period at 3 referral centres and their management according to consensus guidelines of the European and the North American Neuroendocrine Tumor Societies (ENETS and NANETS, re- oped disease recurrence. Five-and 10-year overall survival for all patients with ANEN as the only malignancy was both 99.05%. Conclusions: The current guidelines appear effective in identifying ANEN patients at risk of harbouring nodal disease, but they question the oncological relevance of ANEN lymph node metastases. RH might present an overtreatment for a number of patients with ANEN.
Introduction
Neuroendocrine neoplasms (NEN) are a diverse collective of tumours most commonly arising from the gastroenteropancreatic and bronchopulmonary tracts. Appendiceal NEN (ANEN) constitute 38% of all gastrointestinal NEN, and represent up to 87.9% of all tumours originating from the appendix [1] . Depending upon the geographic region and ethnicity an annual incidence of 0.03-0.16 cases per 100,000 [2, 3] has been reported, and in absolute terms, the incidence of ANEN has increased by 70-133% [4] . There is no gender-specific difference in incidence. Appendiceal NEN are often discovered incidentally on histopathological examination of appendectomy specimens or during abdominal surgery for other indications. Often considered indolent, the risk of disease dissemination remains, as shown in a recent analysis of the Surveillance, Epidemiology, and End Results (SEER) Program database demonstrating that 49% of reported appendiceal tumours (albeit not all "pure" NEN) had lymph node metastases [5, 6] . Approximately 9% may have distant metastases, the risk of which is directly proportional to tumour size, particularly evident in tumours of >2 cm [5] . Existing data on incidence and tumour stage derived from cancer registries should be taken with caution, since small ANEN are sometimes considered as uniformly benign and not recorded. Furthermore, other types of more aggressive appendiceal tumours such as goblet cell cancers (GCC) or mixed adenoneuroendocrine carcinomas are frequently included in the same group. This is reflected in the observation that the rates of distant and regional metastases of 12 and 28%, respectively, reported in the SEER database for appendiceal NEN are higher than those reported in case series that include solely "pure" ANEN [7] .
The mainstay of treatment for ANEN remains surgical, with simple appendectomy or right hemicolectomy (RH) with lymphadenectomy according to oncologic principles. The latest consensus guidelines proposed by the ENETS published in 2016 [8] (initial guidelines in 2012 [9] ) suggest that well-differentiated ANEN <1 cm in size may be managed with appendectomy, unless located at the base of the appendix. However, patients with tumours 1-2 cm in size with positive resection margins or with deep mesoappendiceal invasion, a higher proliferation rate (Ki-67 labelling index >2%), and/or angioinvasion, as well as all patients with tumours exceeding 2 cm, should receive an oncological RH within 3 months after appendectomy [8] . According to the NANETS consensus guidelines, RH is recommended in the presence of tumour invasion at the base of the appendix, for tumours >2 cm in size (or when their size cannot be clearly estimated), if there is evidence of lymphovascular or mesoappendiceal invasion, in patients with mesenteric lymph node metastases, and for intermediate or high-grade tumours [3] .
The data pertaining to recurrent disease in ANEN are scarce due to both the rarity and the indolent nature of the disease, and studies demonstrating a survival benefit associated with RH compared to simple appendectomy only are lacking. Therefore, controversy exists regarding the indications for further segmental colonic resection, and there is debate as to whether the use of RH constitutes overtreatment or if it is oncologically adequate. This uncertainty is most marked for intermediate-sized lesions, i.e., those between 1 and 2 cm in size [8] . The uncertainty is further fostered by reports on lymph node metastases in patients who underwent RH for tumours <1.0 or ≤2.0 cm [10] [11] [12] and in patients with tumours >2.0 cm and negative lymph nodes [13] . Differences in the current TNM staging systems for ANEN, e.g., Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) versus ENETS (Table 1) methods, may further contribute to the controversy.
Here, we report a retrospective review of patients undergoing appendectomy at 3 centres -(1) St Mark's Hospital, London, UK, (2) Imperial College London Healthcare NHS Trust, London, UK, and (3) Maria Skłodowska Curie Memorial Cancer Center, Warsaw, Poland -which identified patients with a confirmed diagnosis of ANEN. We evaluate the management of ANEN patients in light of the most recent guidelines and analyse disease recurrence and overall survival outcomes [3, 8] .
Patients and Methods
We retrospectively reviewed all consecutive patients who underwent an appendectomy either as an isolated procedure or as part of another abdominal surgical procedure at St Mark's Hospital, Imperial College London Healthcare NHS Trust, and Maria Pawa et al. Patient data were entered into a prospectively maintained database at all sites. The study inclusion criteria were (1) histologically confirmed ANEN according to standard histopathology criteria (other appendiceal tumours, e.g., GCC or mixed adenoneuroendocrine carcinoma, were excluded) and (2) undergoing an abdominal surgical procedure involving appendectomy. All histopathology reviews were performed by 1 specialist pathologist at each institution. Basic demographics, biochemical data, and histopathological information including grading and TNM staging (with histology and imaging) according to the ENETS/WHO [14] and UICC/AJCC [15] classifications, respectively, were collated from individual patient notes. In case of potential disagreement between the classification systems, the ENETS classification was considered. Approval for the collection and analysis of patient data in this retrospective study was obtained from the institutional audit/ethics boards of each participating centre in accordance with national standards, including approval REC07/MRE09/54 at Imperial College London.
The ENETS criteria for surgical therapy of ANEN [9] were used to evaluate all study subjects -these guidelines are detailed in Table 2. In cases of patients undergoing colonic resection as a second intervention, the results of the specific diagnostic workup (i.e., cross-sectional imaging, somatostatin receptor-based imaging, and NEN-specific biochemistry) preceding RH were recorded. To attain optimal information regarding disease stage, and for better surgical planning, all patients considered for RH underwent somatostatin receptor-targeted imaging, either with 99m Tc- Ga-DOTATATE PET/CT. The management of patients was discussed within multidisciplinary team settings at all centres.
Thirty-day morbidity and mortality data were collated. Length of follow-up was calculated from the date of the surgery involving appendectomy. The follow-up protocols were according to the ENETS guidelines and uniform among the 3 institutions. For patients undergoing simple appendectomy alone (i.e., those with tumours <1 cm, with R0 resection), no specific follow-up was carried out. For those patients who underwent oncological RH for tumours <2 cm, with no lymph node metastases or residual disease, there was no specific follow-up. For patients with lymph node or any other metastases, follow-up occurred 6-to 12-monthly and thereafter annually with CT or preferably MRI and tumour biochemistry -if there were any pathological increases in tumour markers or findings on morphologic imaging, 68 Ga-DOTATATE PET/CT or Tektrotyd ® WB-SPECT/CT would be carried out. Patients who were eligible for but did not receive completion RH were also followed up 6-to 12-monthly initially and then annually with CT or preferably MRI and tumour-specific biochemistry.
Patient survival status at the last follow-up date (31st December 2015) was ascertained by reviewing patient notes, contacting the patient's general practitioner, or the patients themselves. Patients lost to follow-up were deemed "alive" at the last known clinical encounter. Survival was only formally assessed with the KaplanMeier methodology for patients with ANEN as the only malignancy, i.e., patients with synchronous second malignancies were not included in these analyses. The unpaired t test was used in the comparison of means, whilst associations between categorical 
.2).
We performed a subgroup analysis of all patients that underwent RH to evaluate the guidelines in terms of appropriately selecting ANEN patients for further surgical intervention [3, 8] .
Results
During the study period, 14,850 appendectomies were performed within the 3 centres, and 215 patients (1.45%) had a histologically confirmed diagnosis of ANEN. Four of the included patients (1.86%) had synchronous second abdominal malignancies (colonic adenocarcinoma in 2 cases and ileal neuroendocrine neoplasia in 2 cases). There were no significant differences between the patients from each centre in terms of gender, age at diagnosis, tumour grade, or the incidence of lymph node or distant metastases (all p > 0.05), thus allowing them to be analysed as a single cohort.
The mean age of the ANEN cohort was 33.2 years (range 9-79), and 130 (60.5%) were female. Index appendectomy was performed in 193 cases (89.8%). On 16 patients (7.4%), RH was performed as the index operation for a colonic adenocarcinoma (n = 2), ileal NEN (n = 2), perforated colon (n = 2), right-sided diverticular disease (n = 3), suspected and histologically confirmed ANEN of >2 cm (n = 2), an identified caecal pole abnormality (n = 2), inflammatory bowel disease (n = 1), colonic polyps (n = 1), or an enlarged appendix identified on CT pneumocolon (n = 1). One patient underwent a subtotal colectomy, and 2 patients with familial adenomatous polyposis underwent a panproctocolectomy within which a tumour within the appendix was identified. The 3 remaining cases underwent abdominal surgery for gynaecological indications, wherein an abnormal appendix was resected. Table 3 demonstrates the demographic, operative, and pathological characteristics of the ANEN patients. The mean tumour size was 9.8 mm (range 1-50); in 100 cases (46.5%) the size was <10 mm (T1), 52 patients (24.2%) had lesions between 10 and 20 mm (T2), and 63 tumours (29.3%) were >20 mm (T3 or T4) (TNM staging according to ENETS guidelines [8] ). Seventeen patients (7.9%) had lesions invading the periappendicular fat, and 32 (14.9%) demonstrated serosal invasion of the appendiceal wall (Table 3) . Seventeen patients (7.9%) had involved lymph nodes within the appendiceal mesentery, and 14 (6.5%) demonstrated signs of vascular invasion. A positive resection margin was seen in 9 cases (4.2%), all of which subsequently underwent RH.
Regarding the ENETS tumour grade (G), 200 patients (93%) had G1 tumours (Ki-67 index <2%), 9 (4.2%) had G2 tumours (Ki-67 index 3-20%), and 1 (0.5%) had a G3 tumour (Ki-67 index 25%). The median Ki-67 index was 1% (range 1-25). For 5 patients (2.3%) no tumour grade was available and there was insufficient material for retrospective immunostaining. All patients with G2 and G3 tumours had locoregional lymph node metastases. Two patients had liver metastases (0.9%); an ANEN diagnosis was made in both at the time of explorative laparoscopy for assessment of multifocal liver metastases. The tumour stage was T2N0M1 in one case and T3N1M1 in the other; one patient (stage T2) had a G1 tumour (Ki-67 index 2%) and the other a G2 tumour (Ki-67 index 8% in the primary tumour and 12% in the lymph nodes and liver metastases). In the former patient, the primary tumour was 8 mm in diameter but displayed invasion of both the muscularis propria and the mesoappendix.
Of 193 patients undergoing index appendectomy, 49 (25.4%) underwent subsequent oncologic RH on the basis of the histopathological analysis. In this subgroup, 5 (10.2%) had T1, 24 (49%) had T2, 16 (32.7%) had T3, and 4 (8.2%) had T4 tumours (according to the ENETS criteria [8] ). All of the 29 patients with T1 or T2 lesions fulfilled at least 1 ENETS criterion for RH (Table 2) . Lymph node metastases were present in 12 patients (24.5%), 7 of whom had T1/2 primary tumours. For these 7 patients, the indications for RH were either location at the base of the appendix and incomplete margins (n = 4) or angioinvasion (n = 3). The percentages of 30-day morbidity and mortality following RH were 2 and 0%, respectively (all morbidity was Clavien-Dindo grade 1) [16] . Pathological radiotracer uptake on Tektrotyd ® or 68 Ga-DOTATATE PET/CT at any stage of the patient's journey was only observed in the 2 patients with liver metastases. In the patient with a T3 tumour and liver metastases, hepatic and appendiceal pathological tracer uptake was seen (Fig. 1) . The serum chromogranin A and B levels were within normal ranges prior to RH in all patients except in the patient with liver metastases. After a median follow-up of 38.5 months (range , no patient that had ANEN as the only malignancy (n = 211) and underwent simple appendectomy as the only procedure, appendectomy in the context of other abdominal surgery, or completion RH developed recurrent disease. Of those undergoing simple appendectomy, 23 (11.9%) were lost to follow-up; these patients were either no longer registered with their initial GP, not possible to contact, or had moved back to their native country.
There were 5 patient deaths in the entire study cohort. One patient each died 13 and 31 months after surgery, respectively -both underwent RH as an index operation for a known ileal NEN and had incidentally detected ANEN. Another patient was synchronously diagnosed with colorectal carcinoma and died 20 months after the diagnosis due to colonic cancer progression. A 64-yearold patient with liver metastases of a G2 ANEN had severe carcinoid syndrome and died 9 months after the initial diagnosis despite challenging multimodal treatment with surgery, somatostatin analogues, and chemotherapy. This patient was highly symptomatic with diarrhoea and dehydration. In addition, he developed adrenal insufficiency (normal adrenal glands on imaging) and required corticosteroid supplementation. The other ANEN patient with distant metastases aged 58 years survived 23 months after explorative laparoscopy including appendectomy and underwent treatment with somatostatin analogues and lutetium-177 peptide receptor radionuclide therapy. Otherwise, there were no ANEN-specific deaths either in the appendectomy-only group or in the subset undergoing RH after initial appendectomy. Five-and 10-year overall survival for all patients with ANEN as the only malignancy (n = 211) was both 99.05%. Recurrence-free survival at 5 and 10 years was both 100%.
Retrospectively applying current guidelines throughout the study period would have resulted in 15 additional patients for whom completion oncologic RH would have been indicated but was not performed. Of these, 1 had a T1 tumour, 2 had T2 tumours, 9 had T3 tumours, and 3 had T4 tumours with no evidence of lymph node metastases on imaging. All 3 patients with T1 or T2 tumours fulfilled at least 1 ENETS criterion for RH (Table 2) . Reasons for not undergoing further resection comprised patient choice (reluctance to have a second, more invasive procedure which may be overtreatment), significant co-morbidities conferring an unacceptable surgical risk, or lack of consensus within the multidisciplinary team regarding the benefits of RH. None of these patients developed imaging-detectable locoregional or distant disease recurrence or died during a median follow-up of 31 months (range 14-138). Figure 2 summarises the treatments and outcomes of the cohort.
Discussion
Although ANEN are mostly considered as indolent tumours that can be treated with simple appendectomy, a number may still develop metastatic disease to regional lymph nodes and rarely to the liver and abdominal cavity [12] . The presence of a number of histopathological features has been thought to identify patients at risk, and RH has been proposed as the further surgical approach (Table 4). However, the additional value of RH has been evaluated in only a small number of studies with cohort sizes not exceeding 30 subjects, demonstrating that approximately 30-40% may have residual disease [11, 13, 17] . Our review of more than 200 appendectomies performed for ANEN is the largest reported non-registry-based analysis of a surgical cohort. We found that when recently suggested criteria for the treatment of ANEN are employed, the following may be observed: (1) simple appendectomy is a curative measure in approximately 90% of patients with G1 tumours; (2) of patients selected for subsequent RH, approximately a quarter will be found to have lymph node metastases at reoperation; (3) liver metastases are present in <1% of patients (2 out of 211 who had only ANEN); and (4) thermore, we have demonstrated the limitations of the currently available imaging and biochemical technology for the presently recommended follow-up for patients with ANEN. A predictive value of tumour size has been reported in numerous studies and is considered in the ENETS and NANETS guidelines as a reliable guide for surgical management of ANEN [8, [18] [19] [20] [21] . Additionally, the presence of small vessel invasion has been identified to be a significant arbiter of dissemination. In the largest singlecentre series of ANEN reported in the past 2 decades (n = 79), Kleiman et al. [22] demonstrated that tumours <2 cm in size but with small vessel invasion had the same metastatic potential as tumours ≥2 cm.
The seminal papers by Moertel et al. [23, 24] comprised 150 patients with ANEN followed up for 25 years. None of the patients with tumours <2 cm developed lymph node or distant metastases. One of 12 patients with tumours >2 cm managed initially with appendectomy developed local and nodal recurrence 29 years later, underwent RH, and remained disease free for a further 17 years. The remainder of the patients with tumours >2 cm remained disease free. Only 2 patients from a group of 7 with tumours >2 cm managed with RH had micrometastases in the regional lymph node basin, but they remained disease free within a median follow-up period of 11 years.
More recent studies have implied a favourable tumour biology and questioned the relevance of a positive nodal status. In the analysis by Mullen and Savarese [5] , the 10-year survival of patients with lymph node metastases from primary tumours of any size was >90%. In the study by Kleiman et al. [22] , which advocated RH for tumours <2 cm with small vessel invasion, recurrence was seen only in 1 of 8 patients with lymph node metastases (liver metastases approx. 6 months after primary surgery) and in none of the patients with localised ANEN, but overall survival was 100% in both groups.
Based on the minimal effect on patient survival in their group, Bamboat and Berger [13] criticised the need for RH, recognising morbidity rates of up to 30% together with other long-term complications, particularly in the elderly. Ciarrocchi et al. [25] utilised a propensity score model and showed that simple appendectomy was not inferior to RH regarding survival in patients with ANEN >2 cm. In the analysis of 114 cases of paediatric ANEN by de Lambert et al. [26] , 10 patients had tumours >2 cm and 20 patients had extension into the mesoappendix, including 5 with lympho-/vascular invasion. Ten of 29 cases with indications for hemicolectomy underwent further resection; however, no specimens demonstrated evidence of residual disease. The authors concluded that appendectomy alone is curative, with any further resection or follow-up being unnecessary. From all these studies, there appears to be a discrepancy between residual disease and overall outcome -although patients with residual disease and thus at risk of recurrence are identified, it appears to exert no major effect on overall survival.
The ENETS and NANETS consensus guidelines recognise the difficulty associated with intermediate-sized lesions (T2; 1-2 cm) insofar as lymph node or distant metastases can possibly develop although they are not common [8] . Therefore, in the event of other high-risk features such as tumour location at the base of the appendix, mesoappendiceal invasion, or a positive resection margin, RH is recommended by both NANETS and ENETS guidance. Grozinsky-Glasberg et al. [11] evaluated the ENETS recommendations with their series of 28 patients on whom RH was performed for ANEN, showing that in 18% of them residual disease would be missed if they were operated on according to ENETS criteria. However, there are no data regarding the long-term effect of residual disease on either recurrence-free or overall survival rates.
Our results suggest that the current guidelines are effective in identifying ANEN patients at risk of harbouring With the caveat of a limited sensitivity of the currently utilised follow-up measures, no patients demonstrated disease recurrence, even those patients who were managed with an appendectomy who under the (later introduced) ENETS guidelines would have been selected for hemicolectomy.
In our patient set, all patients undergoing RH for nondistantly metastatic ANEN as the only malignancy were alive and disease free at the last follow-up; indeed the only deaths after RH occurred among patients with second primary malignancies and concomitantly discovered ANEN, or with synchronous liver metastases. These data are in line with those of Steffen et al. [27] , who demonstrated in their cohort of 79 patients that such second primary tumours exert a significant detriment to long-term survival, but they could not demonstrate a statistically significant influence of extended operations for ANEN on prognosis. The fact that 14.9% of our patients with ANEN as the only malignancy had tumours invading the serosa but no peritoneal deposits -as often seen in colorectal cancer in this stage of disease -further underlines the unique biological behaviour of ANEN. We are aware that the relatively short follow-up of the patients in this study might limit our conclusions derived from the results.
In our cohort, somatostatin receptor-based imaging and standard tumour markers for NEN were not useful in patient management, most probably due to the fact that the volume of locoregional disease was very low and below the sensitivity thresholds for these methods. It is questionable whether these modalities can be used with high predictive value in at-risk patients, as they were negative even when employed in patients who were later found to have residual disease. We speculate that in the future, measurement of circulating tumour transcripts or other "omics"-based novel biomarkers may be helpful to identify neuroendocrine tumour disease in this setting [28] . Although we studied the roles of biochemical and radiological follow-up in our cohort, the optimal followup strategy remains elusive for this tumour type.
The surgical management of ANEN remains controversial, particularly for intermediate-sized tumours. Given the predicaments pertaining to predicting the behaviour of ANEN as mentioned above, it is likely that for some patients an RH represents overtreatment. Probable too is that in some patients undergoing simple appendectomy, undetected lymph node metastases remain in situ, or may develop later but remain clinically silent. Such phenomena question the impact of lymph node metastases on the outcome of patients with this challenging disease. Another "dark area" is the true incidence of distant metastases in ANEN, since the quality of the data available in the literature does not provide enough evidence for any robust conclusion. In our cohort, only 2 patients had liver metastases. Of note, in both cases there were synchronous bilobar metastases, and both patients died due to disease progression within 2 years after the diagnosis despite multimodal treatment. We are aware that this is an unexpectedly low survival rate for patients with G1/G2 neuroendocrine liver metastases offered multimodal treatment. One of these patients had carcinoid syndrome, which is exceptionally rare in ANEN and limited to scarce case reports. Accurate classification and staging of these tumours is pivotal for treatment decisions; however, the optimal management algorithm is yet to be elucidated, and as mentioned above the role of formal follow-up for ANEN is unclear [8] .
Further research into the biology of ANEN and novel information beyond standard staging/grading data is required, together with large-scale international collaboration, to identify factors predicting metastatic spread and the survival benefit from further resection. Elevated tumour tissue expression of NAP1LI, MAGE-D2, and MTA1 has been reported in "malignant appendiceal carcinoids" and GCC (i.e., with local invasion, nodal metastases, or liver metastases) compared to "non-invasive carcinoids" incidentally identified during surgery for acute appendicitis, which is suggestive of differential molecular signatures for aggressive and indolent ANEN [29] .
Ideally, the contention surrounding the surgical approach would be addressed by a randomised clinical trial comparing survival and recurrence outcomes in patients treated with appendectomy only and additional oncologic resection. However, due to the protracted follow-up period required as well as the relative rarity of the disease, such a trial would in all likelihood be unrealistic. Presently, consideration of the current guidelines for the surgical management of ANEN patients and detailed counselling should be the "gold standard," bearing in mind that a number of patients may be overtreated. A longterm follow-up of the cohort presented in this study -if technically possible -may contribute to an understanding of the risk of recurrence in ANEN.
Overall, the management of ANEN represents a conflicting clinical situation: the risk of disease recurrence may be low in the long run, but the impact of such recurrence may be significant and must be balanced against the risks of surgical morbidity/mortality. Our data offer a platform for reconceiving the present surgical management and follow-up of ANEN patients and have the potential to stimulate a revision of the guidelines.
